JGH open : an open access journal of gastroenterology and hepatology · 2026
Golgi Protein 73 and Laminin-γ2 Monomer-Based Score for the Diagnosis of Advanced Liver Fibrosis in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ng Xin-Tong, Teh Jin-Ying, Sthaneshwar Pavai, Badaruddin Izzatul Aliaa, Puspanathan Pavitratha, Nik Mustapha Nik Raihan, Mahadeva Sanjiv, Chan Wah-Kheong
Аннотация
BACKGROUND: This study evaluated the diagnostic performance of Golgi protein 73 (GP73), laminin-γ2 monomer (LG2m), and the GLAS score in detecting advanced fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
METHODS: This study included patients with MASLD who underwent liver biopsy. The performance of serum levels of GP73 and LG2m and the GLAS score to diagnose advanced fibrosis was evaluated using area under receiver operating characteristic curves (AUROC).
RESULTS: The data for 209 patients with MASLD were analyzed [median age 52 (42-58) years, 53.1% men, 71.3% had steatohepatitis, 18.1% had advanced fibrosis]. The serum levels of GP73 and LG2m and the GLAS score were significantly higher in patients with advanced fibrosis compared to patients without advanced fibrosis [GP73: 83 ± 50 ng/mL vs. 61 ± 35 ng/mL, p = 0.013; LG2m: 31 (14-48) pg/mL vs. 17 (12-23) pg/mL, p < 0.001; GLAS score: 0.89 (0.49-0.97) vs. 0.47 (0.15-0.78), p < 0.001]. The AUROC of serum levels of GP73 and LG2m and GLAS for diagnosing advanced fibrosis was 0.63 (0.52-0.74), 0.73 (0.62-0.83), and 0.72 (0.61-0.82), respectively. Using the optimal cut-off of 27 pg/mL, the sensitivity, specificity, positive predictive value, and negative predictive value of LG2m for diagnosing advanced fibrosis were 60.5%, 86.0%, 48.9%, and 90.7%, respectively. Using the optimal cut-off of 0.75, the corresponding values for the GLAS score were 65.8%, 73.7%, 35.7%, and 90.6%, respectively.
CONCLUSION: Serum LG2m level and the GLAS score have fair accuracy for the diagnosis of advanced fibrosis in patients with MASLD.
METHODS: This study included patients with MASLD who underwent liver biopsy. The performance of serum levels of GP73 and LG2m and the GLAS score to diagnose advanced fibrosis was evaluated using area under receiver operating characteristic curves (AUROC).
RESULTS: The data for 209 patients with MASLD were analyzed [median age 52 (42-58) years, 53.1% men, 71.3% had steatohepatitis, 18.1% had advanced fibrosis]. The serum levels of GP73 and LG2m and the GLAS score were significantly higher in patients with advanced fibrosis compared to patients without advanced fibrosis [GP73: 83 ± 50 ng/mL vs. 61 ± 35 ng/mL, p = 0.013; LG2m: 31 (14-48) pg/mL vs. 17 (12-23) pg/mL, p < 0.001; GLAS score: 0.89 (0.49-0.97) vs. 0.47 (0.15-0.78), p < 0.001]. The AUROC of serum levels of GP73 and LG2m and GLAS for diagnosing advanced fibrosis was 0.63 (0.52-0.74), 0.73 (0.62-0.83), and 0.72 (0.61-0.82), respectively. Using the optimal cut-off of 27 pg/mL, the sensitivity, specificity, positive predictive value, and negative predictive value of LG2m for diagnosing advanced fibrosis were 60.5%, 86.0%, 48.9%, and 90.7%, respectively. Using the optimal cut-off of 0.75, the corresponding values for the GLAS score were 65.8%, 73.7%, 35.7%, and 90.6%, respectively.
CONCLUSION: Serum LG2m level and the GLAS score have fair accuracy for the diagnosis of advanced fibrosis in patients with MASLD.